CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended		178 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Revenues:
Grant revenue	$ 200,400	$ 1,342,200	$ 12,963,100
Collaboration revenue			2,283,600
Other			1,123,500
Total revenues	200,400	1,342,200	16,370,200
Operating expenses:
Research and development	3,430,800	5,388,600	29,555,700
Acquired in-process research and development			7,523,200
General and administrative	3,562,700	4,997,000	30,681,100
Total operating expenses	6,993,500	10,385,600	67,760,000
Loss from operations	(6,793,100)	(9,043,400)	(51,389,800)
Other expenses, net:
Interest expense, net	(920,700)	(1,893,200)	(10,362,200)
Change in put and note extension option and warrant liabilities	(1,635,800)	(78,000)	(1,217,300)
Loss on early extinguishment of debt	(3,567,800)	(1,193,500)	(4,761,300)
Other income	34,400	200	81,900
Loss before income taxes	(12,883,000)	(12,207,900)	(67,648,700)
Income taxes	(3,700)	(1,600)	(20,500)
Net loss	(12,886,700)	(12,209,500)	(67,669,200)
Deemed dividend on Series A Preferred stock	(10,193,200)		(10,193,200)
Net loss attributable to common stockholders	(23,079,900)	(12,209,500)	(77,862,400)
Basic and diluted net loss per common share	$ (1.27)	$ (0.83)
Weighted average shares used in computing basic and diluted net loss per common share	18,108,444	14,736,651
Comprehensive loss	$ (12,886,700)	$ (12,209,500)	$ (67,669,200)